Jupiter Life Line Hospitals Ltd (JLHL) Q1 FY27 Results Analysis: PAT Slips 14.6%, Margin Pressure Persists
Jupiter Life Line Hospitals Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 410.98 Cr (+16.44% YoY) and PAT growth of -14.58% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 31, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 410.98 Cr (+16.44% YoY) |
| PAT (Q1) | Rs. 37.49 Cr (-14.58% YoY) |
| EBITDA margin | 19.29% (-293 bps YoY) |
| EPS (Q1) | Rs. 5.72 (-14.50% YoY) |
| Market cap | Rs. 10,870.84 Cr |
| CMP | Rs. 331.50 |
Quarter Snapshot
JLHL delivered strong revenue growth of 16.4% YoY, driven by the mature hospitals and the first full quarter from Dombivli. However, costs grew faster (22% YoY), compressing EBITDA margin by 293 bps and causing PAT to decline 14.6% YoY. The Dombivli ramp-up is on track as per management's guidance, but near-term margin pressure is expected to persist until occupancy improves.
Key Investment Insights
Key Positives
- Revenue grew 16.4% YoY to Rs.410.98 Cr, with standalone mature hospitals growing 18.2% YoY
- Dombivli contributed Rs.67 Cr revenue in its first full quarter, demonstrating early traction
- Effective tax rate fell to 25.80% from 28.83% YoY, partially cushioning PAT decline
- Leverage remains manageable at ~1.3x net debt/EBITDA, within the 3x ceiling
- Auditor's report unmodified opinion on standalone and consolidated results
Risk Factors
- EBITDA margin compressed 293 bps YoY to 19.29%, driven by cost growth outpacing revenue
- PAT declined 14.6% YoY to Rs.37.49 Cr, despite revenue growth
- Finance costs surged 55.5% YoY to Rs.12.86 Cr, reflecting higher debt for Dombivli
- Professional fees grew 23.6% YoY and other expenses grew 26.3% YoY, both faster than revenue
- Interest coverage compressed from ~9.5x to ~6.2x, increasing financial risk
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.